Spero Therapeutics SPRO

Drug Manufacturers - General, Healthcare

$1.11

−1.77%

Market cap: $64.6M
PE: 10.1×; 3y median 9.5×
Forward PE: n/m; not a meaningful number
Price to sales: 1.4×
EV/EBIT: 2.1×
Revenue, 12 months: $47M; −3% on a year ago
Net margin: 15.7%
Free cash flow yield: n/m; not a meaningful number

Spero Therapeutics trades at 10.1× trailing earnings, near its ten-year median. Revenue was $47M over the last twelve months, down 3% on a year earlier with a 16% net margin.

Charts

Financials

Income statement for SPRO, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
	$25.5M+1170%	$73.5M+55%	$9.3M+348%	$10.2M+275%	$13.5M−47%	$15M−80%	$5.9M−37%	$14.2M+39%	$5.4M−60%	$41.3M+175%	$258K−96%	$0
R&D	$16.4M+123%	$16.6M+10%	$17.3M+93%	$23.7M+150%	$26.9M+64%	$28.8M+74%	$13.6M−22%	$10.7M−55%	$8.6M−68%	$5.6M−81%	$2.9M−79%	$3.4M−68%
SG&A	$5.7M−14%	$6.4M−1%	$5.9M−19%	$5.5M−9%	$5.2M−9%	$7.1M+10%	$6.8M+15%	$5.9M+6%	$4.2M−20%	$4.3M−39%	$4.9M−28%	$6.5M+10%
	−$1.9M−84%	$50.5M+95%	−$14M−2%	−$19.1M+48%	−$18.6M+861%	−$21.7M	−$14.7M+5%	−$2.4M−87%	−$7.9M−57%	$31.4M	−$7.5M−49%	−$9.9M+306%
Interest expense	$0	$0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pre-tax income	−$994K−92%	$51.6M+93%	n/a	n/a	−$17.4M+1654%	−$20.6M	n/a	n/a	−$7.4M−58%	$31.8M	n/a	n/a
	$2.2M	$387K	n/a	n/a	$290K−87%	−$290K	n/a	n/a	$0	$261K	n/a	n/a
Net income	−$3.2M−73%	$51.2M+91%	−$12.7M−5%	−$17.9M+50%	−$17.1M+435%	−$20.9M	−$13.9M+9%	−$1.7M−91%	−$7.4M−57%	$31.5M	−$7.2M−48%	−$9.6M+462%
	−$0.06−82%	$0.96−61%	−$0.24−4%	−$0.33+44%	−$0.32+433%	−$0.38	−$0.25+4%	−$0.03−91%	−$0.13−59%	$0.53	−$0.13−48%	−$0.16+433%
	52.7M+47%	53.3M+9%	53.5M+2%	54M+3%	54.1M+3%	54.5M+2%	55.4M+4%	56M+4%	56.3M+4%	59.5M+9%	57.3M+3%	58M+4%

Revenue: Q1 FY17: 6 months less the 3 months printed beside them.

EPS, diluted: 7 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 4 periods, Q4 FY18 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY25: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Spero Therapeutics' size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
SPROSpero Therapeutics	$64.6M	10.1×	9.5×	1.4×	−3%	15.7%
LFVNLifevantage	$73.4M	14.7×	19.6×	0.4×	−20%	2.8%
ATNMActinium Pharmaceuticals	$47.8M	4.2×	3.1×	n/m	n/m	n/m
NATRNatures Sunshine Products	$213.8M	12.0×	20.6×	0.4×	+7%	3.7%
ARVNArvinas	$477.3M	45.6×	52.3×	1.5×	−15%	2.9%
PBYIPuma Biotechnology	$568.9M	21.2×	12.3×	2.5×	−3%	11.6%
IRWDIronwood Pharmaceuticals	$571.7M	4.5×	14.9×	1.5×	+26%	33.4%
ZVRAZevra Therapeutics	$582.6M	10.5×	12.3×	4.3×	+119%	42.8%
CRMDCorMedix	$611.9M	3.7×	4.0×	1.3×	+281%	40.5%
Peer median	$523.1M	11.3×	13.6×	1.5×	+7%	11.6%